Health Care·Biotechnology·$351.5B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.82 | N/A | +3.80% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.82 | N/A | +3.80% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a sense of cautious optimism regarding the company's performance. They emphasized their commitment to innovation and growth.
Management expressed satisfaction with the EPS performance despite the lack of revenue details.
They highlighted ongoing efforts to strengthen their product pipeline.
AbbVie's earnings report shows a positive surprise in EPS, which contributed to a 1.24% increase in stock price. The lack of revenue data leaves some uncertainty, but management's focus on product development suggests a strategic approach moving forward. Investors may view the EPS beat as a sign of resilience in the company's financial health.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
LOCKHEED MARTIN CORP
Jul 23, 2013